Bristol Myers Squibb Presents First Phase 3 Data on KarXT for Alzheimer’s Psychosis
The company presented clinical data from two Phase 3 ADEPT studies evaluating KarXT for psychosis associated with Alzheimer’s disease.
The company presented clinical data from two Phase 3 ADEPT studies evaluating KarXT for psychosis associated with Alzheimer’s disease.